Trial result ·
Impact of organic selenium supplementation on glycaemic control and quality of life in patients with diabetic neuropathy: a randomized placebo-controlled trial.
Written based on 1 research study on PubMed, searched on 4 Nov 2026.
What was studied
This trial tested selenium, a trace mineral, in people with type 2 diabetes. All 50 people also had nerve damage caused by their diabetes. Each person was put by chance into one of the groups. One group took 200 μg of selenium yeast each day. The other group took a dummy pill. Both groups took their pills for 8 weeks. Neither the people nor the team knew who got what. The team checked blood sugar, how the body used insulin, quality of life and sleep.
What they found
Compared with the dummy pill, selenium lowered blood sugar after a fast. It also lowered HbA1c, which is another blood sugar test. Tests showed the body used insulin better with selenium. Quality of life and sleep got better within the selenium group. But these gains were not clearly bigger than in the dummy pill group. One part of sleep did improve more with selenium. This was how well people coped in the day. Side effects were few, and they were alike in both groups.
What it means for patients
The authors say 8 weeks of selenium helped blood sugar and insulin use. They saw no notable side effects. They think selenium may be a useful extra step alongside other care. This would be for short-term blood sugar control in these people. They also say the drop in HbA1c may matter for health.
Why it is not certain yet
The authors say the results need care before people rely on them. Only 50 people took part. The trial lasted just 8 weeks. It was run at only one centre. The authors say longer studies are still needed. These could also look at wider effects on the nerves and mind.
Source
Impact of organic selenium supplementation on glycaemic control and quality of life in patients with diabetic neuropathy: a randomized placebo-controlled trial.
PubMed · PMID 42631762We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Type 2 diabetes publications